CoChat

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial

Open access
Metra, Marco, Torp-Pedersen, Christian, Swedberg, Karl, Cleland, John G.F., Di Lenarda, Andrea, Komajda, Michel, Remme, Willem J., Lutiger, Beatrix, Scherhag, Armin, Lukas, Mary Ann, Charlesworth, Andrew, Poole-Wilson, Philip A. · 2005 · European Heart Journal

Abstract

AIMS: We studied the influence of heart rate (HR), systolic blood pressure (SBP), and beta-blocker dose on outcome in the 2599 out of 3029 patients in Carvedilol Or Metoprolol European Trial (COMET) who were alive and on study drug at 4 months after randomization (time of first visit on maintenance therapy). METHODS AND RESULTS: By multivariable analysis, baseline HR, baseline SBP, and their change after 4 months were not independently related to subsequent outcome. In a multivariable analysis including clinical variables, HR above and SBP below the median value achieved at 4 months predicted subsequent increased mortality [relative risk (RR) for HR>68 b.p.m. 1.333; 95% confidence intervals (CI) 1.152-1.542; P<0.0001 and RR for SBP>120 mmHg 0.78; 95% CI 0.671-0.907; P<0.0013]. Achieving target beta-blocker dose was associated with a better outcome (RR 0.779; 95% CI 0.662-0.916; P<0.0025). The superiority of carvedilol as compared to metoprolol tartrate was maintained in a multivariable model (RR 0.767; 95% CI 0.663-0.887; P=0.0004) and there was no interaction with HR, SBP, or beta-blocker dose. CONCLUSION: Beta-blocker dose, HR, and SBP achieved during beta-blocker therapy have independent prognostic value in heart failure. None of these factors influenced the beneficial effects of carvedilol when compared with metoprolol tartrate at the pre-defined target doses used in COMET.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehi386

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 40 references

Cited by

See all 187

Metadata

Authors
Metra, M., Torp-Pedersen, C., Swedberg, K., Cleland, J. G. F., Di Lenarda, A., Komajda, M., Remme, W. J., Lutiger, B., Scherhag, A., Lukas, M. A., Charlesworth, A., & Poole-Wilson, P. A.
Affiliations
University of Brescia (IT)
Corresponding author
Metra, Marco
Venue
European Heart Journal
Published
2005-07-21
Volume
26
Issue
21
Pages
2259-2268
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2125268034
Cited by
178
References
40
Citations by year
2026: 1 · 2025: 1 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 4 · 2019: 8 · 2018: 7 · 2017: 9 · 2016: 11 · 2015: 11 · 2014: 7 · 2013: 10 · 2012: 17
FWCI
7.29
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
  • reroDoc Digital Library (submittedVersion)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • GlaxoSmithKline
  • F. Hoffmann-La Roche
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
chronic heart failure, carvedilol, metoprolol tartrate, beta-blockers, heart rate, systolic blood pressure, beta-blocker dose, mortality, prognostic factors, COMET trial, drug comparison
MeSH terms
Carvedilol, Adrenergic beta-Antagonists, Blood Pressure, Carbazoles, Chronic Disease, Dose-Response Relationship, Drug, Double-Blind Method, Female, Heart Failure, Heart Rate, Humans, Male, Metoprolol, Middle Aged, Propanolamines, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehi386
The paper
Metra, M., Torp-Pedersen, C., Swedberg, K., Cleland, J. G. F., Di Lenarda, A., Komajda, M., Remme, W. J., Lutiger, B., Scherhag, A., Lukas, M. A., Charlesworth, A., & Poole-Wilson, P. A. (2005). Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehi386

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.